Articles tagged with: Ninlaro
News»

This year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago, began yesterday and goes through Tuesday.
The first of the myeloma-related sessions at this year's meeting began this morning with a poster session, in which important new research findings were summarized on posters throughout a large conference hall.
MLN9708
This morning’s session included two posters about MLN9708 (ixazomib), an oral drug that works similarly to Velcade (bortezomib) and is being investigated for the treatment of multiple myeloma as well as …
News»

The 48th annual meeting of the American Society of Clinical Oncology (ASCO) will take place Friday, June 1, through Tuesday, June 5, in Chicago.
More than 25,000 clinical specialists from all over the world are expected to attend the five-day meeting to discuss the current research in cancer treatment and care. The theme for this year’s meeting is “Collaborating to Conquer Cancer.”
The meeting will include many presentations and seminars focused specifically on multiple myeloma. The ASCO website currently lists nearly 50 myeloma-based presentations (included under “lymphoma and plasma cell disorders”).
The …
News»

Many new and promising research developments occurred in the field of multiple myeloma during 2011. Over the course of the year, The Myeloma Beacon published nearly 100 articles on important myeloma-related studies.
To identify the most important of these studies from 2011, The Myeloma Beacon surveyed leading physicians and researchers in the field. They were asked to name the three peer-reviewed journal articles published in 2011 and the three conference presentations from 2011 that have the most important findings or implications relating to multiple myeloma.
Their selections for the most important journal …
News»

It has been ten days since the 2011 annual meeting of the American Society of Hematology (ASH) came to a close.
Since the meeting started, The Beacon has been providing detailed coverage in the form of discussion forum postings, daily updates, and in-depth articles about key research findings.
In this and The Beacon's next article about the meeting, however, the perspective changes a bit.
The focus shifts to the bigger picture -- to questions like: "What was the impact of the meeting?", and …
News»

As the third day of the 2011 American Society of Hematology (ASH) annual meeting came to an end, attendees could look back on an agenda that featured presentations about a wide range of potential new myeloma therapies.
The afternoon myeloma sessions were focused, in fact, on potential new therapies.
The Beacon's previous ASH 2011 update covered the afternoon presentations about carfilzomib and pomalidomide, two potential myeloma therapies that are in the late stages of development.
This update covers the afternoon's presentations about four other potential new myeloma therapies -- MLN9708, panobinostat, …
News»

The initial results from three early-phase clinical trials suggest that the investigational drug MLN9708, either alone or in combination with Revlimid and dexamethasone, may be an effective treatment for both newly diagnosed multiple myeloma patients and patients with relapsed and/or treatment-resistant disease.
The findings from the three trials were presented earlier this week at the American Society of Hematology (ASH) annual meeting in San Diego.
MLN9708 (ixazomib) belongs to the same class of drugs as Velcade (bortezomib), called proteasome inhibitors, and it is being developed by Millennium Pharmaceuticals, the same company that developed …
News»

Yesterday was the third day of the American Society of Hematology (ASH) 2011 Annual Meeting in San Diego, and it was packed full with multiple myeloma-related presentations. Presentations started early in the morning and continued through the afternoon.
The morning presentations about potential new myeloma therapies will be covered in this update, and presentations from the rest of the day will be covered in additional updates.
MLN9708
During the first talk of the day, Dr. Paul Richardson from the Dana-Farber Cancer Institute in Boston presented results from a Phase 1 study of …